Antibody drug conjugates are starting to transform cancer treatments, so let’s maintain the momentum.

After a madcap back and forth between leading and dissenting Democrats, Biden’s drug pricing reform plans have reached a compromised final form.

Stating an intention to be ready to win in any biowarzone, the US military has commissioned Dynavax to develop a vaccine for the plague.

In a market filled with complexity, working with a single supplier simplifies the supply chain and focuses effort towards a single target.

A possible fix for problems in small molecule manufacture via continuous flow processing.

Experts discuss how to tackle biopharma's need to move fast.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

Setting its sights on self-amplifying RNA, AstraZeneca has signed a deal with Imperial College London spinoff VaxEquity.

Biotech companies need good patient samples, but hospitals are not always obliging...

Researchers at Trinity College Dublin explain how they are reaching into the natural environment to source new bioactives.